Discovery of orally bioavailable NK1 receptor antagonists
- 1 February 2003
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (3) , 437-442
- https://doi.org/10.1016/s0960-894x(02)00956-3
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Substance P: a pioneer amongst neuropeptidesJournal of Internal Medicine, 2001
- Phosphorylated Morpholine Acetal Human Neurokinin-1 Receptor Antagonists as Water-Soluble ProdrugsJournal of Medicinal Chemistry, 2000
- 4,4-Disubstituted Piperidine High-Affinity NK1 Antagonists: Structure−Activity Relationships and in Vivo ActivityJournal of Medicinal Chemistry, 1998
- Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor AntagonistJournal of Medicinal Chemistry, 1998
- Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonistBioorganic & Medicinal Chemistry Letters, 1998
- A new synthesis of α-arylglycines from aryl boronic acidsTetrahedron, 1997
- Phenyl-glycinol based NK1 receptor antagonists — towards the minimum pharmacophoreBioorganic & Medicinal Chemistry Letters, 1995
- Methylenations of heteroatom-substituted carbonyls with dimethyl titanoceneTetrahedron Letters, 1995
- Piperidine-ether based hNK1 antagonists 1: Determination of the relative and absolute stereochemical requirementsBioorganic & Medicinal Chemistry Letters, 1994
- Discovery of a potent substance P antagonist: recognition of the key molecular determinantJournal of Medicinal Chemistry, 1992